Week of Oct 24–30, 2026

Weekly GLP-1 trial and regulatory updates

Read the public weekly current-awareness feed for changes across GLP-1 and related obesity-drug trials, results, regulatory events, and industry news. Three trial drill-downs are free. Deeper trial drill-down is available with the Plus tier. For focused analysis and context, read the GLP-1 Observer newsletter ↗

New to the mechanism classes? See the GLP-1 Field Guides for plain-English explainers on mono, dual, triple, and combination incretin drugs.

This Week's Highlights

  • Eli Lilly's retatrutide beats Ozempic in Phase 3 TRANSCEND-T2D-2 diabetes trial↗Results
  • Eli Lilly registers 3,000-patient Phase 3 eloralintide trial in obesity with type 2 diabetes↗New Trial
  • Regeneron registers 3,000-patient Phase 3 trial for olatorepatide in obesity↗New Trial
  • Ascletis reports positive Phase 2 results for oral ASC30 in diabetes↗Results
  • Corxel plans $377M SPAC merger to fund Phase 3 GLP-1 trials↗News
  • Novo Nordisk and Andel partner for direct-to-employer Wegovy access↗News

Detailed Updates

Click an NCT badge to open the trial detail drawer.
Phase 3ENDPOINT METEli Lilly's Retatrutide Outperforms Ozempic in Phase 3 TRANSCEND-T2D-2 Trial for Type 2 Diabetes
At 80 weeks, retatrutide lowered A1C by 2.2% and body weight by up to 20.9%, vs 1.8% and 9.4% with Ozempic 2 mg. Discontinuations due to adverse events were 4.8% and 7.9% with retatrutide 9 mg and 12 mg vs 2.7% with Ozempic.
Phase 3GLP-1 OtherEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 3GLP-1/Glucagon DualSYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
Boehringer Ingelheim
Primary Completion Date: 2028-06-25 → 2029-11-06(+499 days)
Also: CompletionDateChanged (+499 days)
Phase 1/Phase 2A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Arrowhead Pharmaceuticals
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
Ascletis' oral GLP-1 candidate ASC30 met its Phase 2 endpoints in type 2 diabetes, with a 1.6% to 1.7% placebo-adjusted HbA1c reduction at 12 weeks. Weight loss in the diabetes cohort trailed Eli Lilly's oral Foundayo.
Source ↗
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
Ascletis submitted an FDA IND for ASC39, an oral small-molecule selective amylin receptor agonist for obesity. It plans to start a Phase 1 trial in late 2026 and to test ASC39 in combination with its oral GLP-1 ASC30.
Source ↗
Corxel claims oral obesity drug is in the ‘right lane’ as biotech plans SPAC route to Nasdaq
Corxel Pharmaceuticals will merge with Amanat Acquisition to secure funding for Phase 3 trials of oral GLP-1 candidate CX11, which previously demonstrated up to 11.5% weight loss over 36 weeks.
Source ↗
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUSâ„¢ (tradipitant) for Prevention of GLP-1-Induced Vomiting
Vanda Pharmaceuticals' Phase 3 Nereus trial succeeded, showing tradipitant significantly reduced the incidence and severity of gastrointestinal side effects compared to placebo after a single dose of Wegovy.
Also covered by: fierce_pharma
Source ↗
Andel Collaborates With Novo To Bring Wegovy® Injection and Wegovy® Pill Direct-to-Employers
Andel and Novo Nordisk partnered to offer Wegovy products directly to employers through Andel's medication marketplace, enabling companies to subsidize costs while bypassing traditional insurance channels.
Source ↗
Eli Lilly fends off Novo’s legal bid to block GLP-1 marketing claims
A U.S. judge denied Novo Nordisk's request for a preliminary injunction against Lilly's Zepbound and Mounjaro comparison ads, citing Novo's own SUSTAIN-7 superiority ads against Trulicity. Novo's false-advertising suit continues.
Source ↗
Phase 4GLP-1 MonoA Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
Novo Nordisk A/S · 300 participants
Novo Nordisk registered a 300-patient Phase 4 study in China evaluating the kidney and heart health impacts of semaglutide in adults with type 2 diabetes and chronic kidney disease.
Phase 3Amylin MonoA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Eli Lilly and Company · 3,000 participants · ENLIGHTEN-10
Eli Lilly registered a 3,000-participant Phase 3 trial of eloralintide in adults with obesity or overweight, type 2 diabetes and increased cardiovascular risk. Primary endpoints are weight change at week 64 and HbA1c at week 36.
Phase 3GLP-1/GIP DualEfficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals · 3,000 participants · RISE-1
Regeneron registered a 3,000-patient Phase 3 trial assessing the efficacy and safety of olatorepatide in adults with overweight or obesity without diabetes.
Phase 1A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes
Novo Nordisk A/S · 121 participants
Novo Nordisk is launching a 121-participant Phase 1 safety study of candidate NNC9836-0001 in healthy participants and participants with type 2 diabetes.